科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

未开盘 10-15 16:08:35

11.110

-0.410

-3.56%

最高11.680	最低10.890	成交量274.05万
今开11.680	昨收11.520	日振幅6.86%
总市值65.99亿	流通市值65.99亿	总股本5.94亿
成交额3,043万	换手率0.46%	流通股本5.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":11.11,"timestamp":1792051715002,"preClose":11.52,"halted":0,"volume":2740500,"delay":0,"changeRate":-0.03559027777777779,"floatShares":594000000,"shares":594000000,"eps":-0.177264,"marketStatus":"未开盘","change":-0.41,"latestTime":"10-15 16:08:35","open":11.68,"high":11.68,"low":10.89,"amount":30432235,"amplitude":0.068576,"askPrice":11.11,"askSize":11500,"bidPrice":11.08,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.173,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792114200000},"marketStatusCode":0,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":11.52,"openAndCloseTimeList":[[1792027800000,1792036800000],[1792040400000,1792051200000]],"volumeRatio":1.42559,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"2675538166","title":"科济药业：CT0596国内I期临床完成首例患者输注","url":"https://stock-news.laohu8.com/highlight/detail?id=2675538166","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675538166?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:32","pubTimestamp":1791855120,"startTime":"0","endTime":"0","summary":"10月13日，科济药业（02171）发布公告，公司研发的CT0596在中国进行的I期注册临床试验已完成首例患者输注。CT0596是一种靶向BCMA的通用型CAR-T细胞产品，主要用于治疗复发/难治的多发性骨髓瘤（R/RMM）患者。该产品的IIT研究结果已在2026年欧洲血液学协会（EHA）年会上进行壁报展示。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610133893612916.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610133893612916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","BK1585","02171","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675854223","title":"科济药业-B(02171.HK)：CT0596在中国I期注册临床试验中完成首例患者输注","url":"https://stock-news.laohu8.com/highlight/detail?id=2675854223","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675854223?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:05","pubTimestamp":1791849938,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","02171","BK1585","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163348297","title":"科济药业-B（02171）通用型CAR-T疗法CT0596在华I期注册临床试验完成首例患者输注","url":"https://stock-news.laohu8.com/highlight/detail?id=1163348297","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163348297?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:05","pubTimestamp":1791849926,"startTime":"0","endTime":"0","summary":"2026年10月13日，科济药业控股有限公司发布自愿公告，旗下靶向BCMA的通用型CAR-T细胞产品CT0596已在中国开展的I期注册临床试验中完成首例复发/难治多发性骨髓瘤患者的输注。\\n\\n科济药业强调，依据香港联交所证券上市规则第18A.05条，CT0596的研发和最终商业化均存在重大不确定性，提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163757013","title":"科济药业-B公布2026年9月股份变动月报表，已发行股本增至594,248,912股","url":"https://stock-news.laohu8.com/highlight/detail?id=1163757013","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163757013?lang=zh_cn&edition=full","pubTime":"2026-10-07 22:05","pubTimestamp":1791381940,"startTime":"0","endTime":"0","summary":"科济药业-B于2026年10月7日发布2026年9月股份变动月报表。根据公告，截至2026年9月30日，科济药业-B已发行股份数量为594,248,912股，较上月底的594,237,547股增加11,365股；当月并未产生库藏股份。公告还指出，公司于2026年7月7日、13日及17日于香港联交所合计回购711,000股普通股，该部分股份截至9月30日尚未注销。截至报告期末，公司已发行股份总数增至594,248,912股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173378941","title":"科济药业-B公布最新董事会及委员会架构","url":"https://stock-news.laohu8.com/highlight/detail?id=1173378941","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173378941?lang=zh_cn&edition=full","pubTime":"2026-09-30 21:13","pubTimestamp":1790773984,"startTime":"0","endTime":"0","summary":"2026年9月30日，科济药业控股有限公司发布公告，披露截至公告日的董事会成员及其在董事会专门委员会中的职能分配。上述安排使公司董事会成员总数为7名，其中独立非执行董事占比约42.86%。公司已设立审计委员会、薪酬委员会以及提名及企业管治委员会。公告未披露除上述事项外的任何财务数据或经营数据。公司提示股东及潜在投资者应参照公告全文了解详情。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147664165","title":"科济药业-B(02171)：非执行董事辞任，审计委员会成员不足触及上市规则","url":"https://stock-news.laohu8.com/highlight/detail?id=1147664165","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147664165?lang=zh_cn&edition=full","pubTime":"2026-09-30 21:06","pubTimestamp":1790773568,"startTime":"0","endTime":"0","summary":"2026年9月30日，科济药业-B公告称，因需投入更多时间处理其他个人事务，非执行董事郭华清已辞任公司董事及董事会审计委员会委员职务，自同日生效。郭华清离任后，审计委员会仅余两名成员，分别为独立非执行董事赵向可（主席）及独立非执行董事周文（委员），不符合《香港联合交易所有限公司证券上市规则》第3.21条关于审计委员会至少三名成员的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671202752","title":"科济药业-B(02171)：郭华清辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2671202752","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671202752?lang=zh_cn&edition=full","pubTime":"2026-09-30 21:04","pubTimestamp":1790773461,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)发布公告，由于需要投放更多时间于其他个人业务，郭华清先生(郭先生)已提出辞任本公司非执行董事，自2026年9月30日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"科济药业-B(02171)：郭华清辞任非执行董事","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1585","BK1161","BK1587","BK1574","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119728552","title":"科济药业-B（02171）：通用型CAR-T疗法CT1190B在中国I期注册临床试验完成首例患者输注","url":"https://stock-news.laohu8.com/highlight/detail?id=1119728552","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119728552?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:10","pubTimestamp":1790640636,"startTime":"0","endTime":"0","summary":"2026年9月29日，科济药业-B公布，公司自主研发的靶向CD19/CD20通用型CAR-T细胞产品CT1190B，已在中国的I期注册临床试验中完成首例复发/难治性大B细胞淋巴瘤患者的输注。CT1190B基于公司THANK-u Plus平台开发，旨在治疗经至少二线标准疗法失败的R/R LBCL患者。科济药业提醒投资者，根据香港联交所证券上市规则第18A.05条，公司无法保证CT1190B能最终成功开发或商业化。公司董事会于2026年9月29日发布本次自愿公告，并提示股东及潜在投资者在买卖公司股份时应审慎行事。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671668112","title":"科济药业-B(02171)：CT1190B在中国I期注册临床试验中完成首例患者输注","url":"https://stock-news.laohu8.com/highlight/detail?id=2671668112","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671668112?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:07","pubTimestamp":1790640467,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)公布，CT1190B，一种靶向CD19/CD20的通用型 CAR-T细胞产品，在中国进行的I期注册临床试验完成首例患者输注，用于治疗至少二线标准治疗失败的复发╱难治性大B细胞淋巴瘤(R/R LBCL)患者。CT1190B 的IIT研究结果，已在2026年欧洲血液学协会(EHA)年会上进行壁报展示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02171","MDTX","IBBJ","BK1587","BK1161","BMED","IBBQ","PSYK","BK1574","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132319354","title":"科济药业-B2026年中期营收62百万元，经调整净利润-32百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132319354","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132319354?lang=zh_cn&edition=full","pubTime":"2026-09-15 18:13","pubTimestamp":1789467183,"startTime":"0","endTime":"0","summary":"科济药业-B在其2026年中期报告中披露，期内实现营收约62百万元，同比去年同期的约51百万元增长约21.6%。经调整净利润为-32百万元，相比去年同期-72百万元明显收窄，降幅约55.6%。公司毛利约42百万元，高于上年同期的29百万元；根据公告推算，本期毛利率约67.7%，相比上年同期约56.9%有所提升。经营现金流方面，2026年上半年经营活动所用现金净额为-130百万元，较上年同期的-196百万元显著提升。行政开支则从上年同期39百万元下降至34百万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"科济药业-B2026年中期营收62百万元，经调整净利润-32百万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667321696","title":"港股异动 | 科济药业-B(02171)午前涨近3% FNC清淋预处理方案获中国专利正式授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2667321696","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667321696?lang=zh_cn&edition=full","pubTime":"2026-09-14 11:54","pubTimestamp":1789358057,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B午前涨近3%，截至发稿，涨2.47%，报12.86港元，成交额1644.03万港元。消息面上，9月14日，据科济药业官微消息，公司自主研发的FNC清淋预处理方案正式获得中国国家知识产权局专利授权。此次FNC清淋预处理方案在中国获得专利授权，意味着公司对恺力美的保护已从单一产品层面，延伸至涵盖清淋预处理在内的整体治疗方案层面，提升了同类竞品的研发与商业化门槛，进一步巩固了公司在实体瘤CAR-T领域的领先地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4588","VXUS","02171","BK1585","BK1161","BK1587","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510692","title":"科济药业-B盘中涨近5% 公司香港业务取得重要进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510692","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666510692?lang=zh_cn&edition=full","pubTime":"2026-09-11 10:42","pubTimestamp":1789094520,"startTime":"0","endTime":"0","summary":"模拟交易客户端科济药业-B盘中涨近5%。科济药业宣布，公司在香港地区的先进疗法产品相关业务取得重要进展，已获得开展相关药剂制品批发供应业务所需的许可资质。此次许可的取得，是科济药业推进恺力美国际化布局的重要里程碑，为公司进一步探索恺力美在香港地区的患者可及路径及相关业务开展奠定了基础，也为公司持续拓展海外市场积累了重要经验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-11/doc-inirmmnc5377838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1585","BK1161","02171","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666517233","title":"港股异动 | 科济药业-B(02171.HK)早盘涨近5% 香港业务取得重要进展 进一步推进恺力美国际化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2666517233","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666517233?lang=zh_cn&edition=full","pubTime":"2026-09-11 10:12","pubTimestamp":1789092731,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1585","02171","BK1161","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160371260","title":"科济药业-B更新2026年8月股份变动月报表，已发行股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1160371260","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160371260?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:33","pubTimestamp":1788521595,"startTime":"0","endTime":"0","summary":"科济药业控股有限公司于2026年9月4日发布截至2026年8月31日止的证券变动月报表。公告显示，公司注册股本维持在200,000,000,000股普通股，面值每股0.00000025美元，总注册股本50,000美元，与上月底保持一致。截至本月月底，若全部期权获行使，公司潜在发行和可转让股份合计23,812,322股。公告还显示，公司已于2026年7月进行711,000股普通股的回购交易，相關股份截至2026年8月31日尚未注销，故本月已发行股本仅出现8,000股的小幅增加，期末已发行股本总数为594,237,547股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124447538","title":"港股生物科技股大涨，思路迪医药股份涨超80%，云顶新耀涨超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124447538","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124447538?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:30","pubTimestamp":1787189405,"startTime":"0","endTime":"0","summary":"8月20日，港股$生物(000504)$科技股大涨，$思路迪医药股份(01244)$涨超80%，$云顶新耀(01952)$涨超60%，$康希诺生物(06185)$涨超50%，$艾美疫苗(06660)$涨超45%，$剂泰科技-P(07666)$涨超25%，$科济药业-B(02171)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VGT","06185","03069","XLK","06660","BK1191","07261","07666","BK1583","01952","BK4585","07568","09086","09834","02834","BK1515","BK1161","01244","03086","03034","02171","BK1587","VXUS","BK1574","BK1585","03455","07266","TTTN","BK4588","KCAI","BK1147","07522"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431074","title":"全球首款实体瘤CAR-T卖99万元，科济药业称销售额在下半年确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431074","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431074?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:08","pubTimestamp":1787126930,"startTime":"0","endTime":"0","summary":"今年6月22日，科济药业（02171.HK）的恺力美作为全球首款治疗实体瘤的CAR-T细胞产品获批国内上市，用于晚期胃癌治疗，但售价高达99万元，究竟会有多少患者愿意买单？随着公司半年报披露，该问题受到投资者关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846256878.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846256878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1585","02171","BK1161","BK1574","BK4230","CAR","BK4022","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660941647","title":"科济药业-B绩后涨近5% 中期收益约为6191.9万元同比增长21.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660941647","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660941647?lang=zh_cn&edition=full","pubTime":"2026-08-19 10:13","pubTimestamp":1787105580,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端科济药业-B（02171）绩后涨近5%，截至发稿，股价上涨4.63%，现报15.38港元，成交额2389.73万港元。8月18日，科济药业-B公布2026年中期业绩，收益约为6191.9万元，同比增长21.5%；经调整净亏损3192.7万元，同比收窄55.53%；母公司拥有人应占亏损6666.3万元，同比收窄11.52%；每股亏损0.13元。公告称，收益增长主要由于赛恺泽®的销量有所增加。经调整净亏损减少主要归因于行政开支减少。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-19/doc-ininvfsy2765577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02171","BK1161","BK1587","BK1574","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660163104","title":"港股异动 | 科济药业-B(02171.HK)绩后涨超4% 中期母公司拥有人应占亏损同比收窄11.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660163104","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660163104?lang=zh_cn&edition=full","pubTime":"2026-08-19 09:51","pubTimestamp":1787104275,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1587","BK1574","02171","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660931174","title":"科济药业-B(02171)公布中期业绩 母公司拥有人应占亏损6666.3万元 同比收窄11.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660931174","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660931174?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:36","pubTimestamp":1787063792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)公布2026年中期业绩，收益约为6191.9万元，同比增长21.5%;经调整净亏损3192.7万元，同比收窄55.53%;母公司拥有人应占亏损6666.3万元，同比收窄11.52%;每股亏损0.13元。公告称，收益增长主要由于赛恺泽®的销量有所增加。经调整净亏损减少主要归因于行政开支减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02171","BK1585","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107735210","title":"科济药业-B（02171）2026年中期收入增至0.62亿元 净亏损收窄至0.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107735210","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107735210?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:31","pubTimestamp":1787063467,"startTime":"0","endTime":"0","summary":"2026年8月18日，科济药业控股有限公司公布截至2026年6月30日止六个月未经审计的中期业绩。报告期内，公司实现收入0.62亿元，同比增长0.11亿元，主要得益于全人源BCMA自体CAR-T产品“赛愷澤”销量增加。同期毛利录得0.42亿元，较上年同期增加0.13亿元；毛利增长同样源于“赛愷澤”销售规模提升。期间净亏损由上年同期的0.75亿元收窄至0.71亿元，减少0.04亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":-0.0695},{"period":"1month","weight":-0.0958},{"period":"3month","weight":-0.3255},{"period":"6month","weight":-0.5373},{"period":"1year","weight":-0.3492},{"period":"ytd","weight":-0.2242}],"compareEarnings":[{"period":"1week","weight":0.0076},{"period":"1month","weight":-0.0242},{"period":"3month","weight":-0.0278},{"period":"6month","weight":-0.0706},{"period":"1year","weight":-0.0443},{"period":"ytd","weight":-0.0514}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科济药业控股有限公司是一家主要从事探索、研发细胞疗法的投资控股公司。该公司的主营业务是从事开发嵌合抗原受体T细胞（CAR-T）细胞疗法，以满足临床需求，包括但不限于血液恶性肿瘤、实体瘤及自身免疫性疾病。该公司的主要产品包括赛恺泽（泽沃基奥仑赛注射液）、舒瑞基奥仑赛注射液、通用型CAR-T细胞产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.07858},{"month":2,"riseRate":0.6,"avgChangeRate":0.230493},{"month":3,"riseRate":0.2,"avgChangeRate":-0.058535},{"month":4,"riseRate":0.4,"avgChangeRate":-0.02351},{"month":5,"riseRate":0.6,"avgChangeRate":0.035849},{"month":6,"riseRate":0.4,"avgChangeRate":-0.015777},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.022715},{"month":8,"riseRate":0.5,"avgChangeRate":0.052678},{"month":9,"riseRate":0.333333,"avgChangeRate":0.020205},{"month":10,"riseRate":0.5,"avgChangeRate":0.006417},{"month":11,"riseRate":0.6,"avgChangeRate":0.051023},{"month":12,"riseRate":0.4,"avgChangeRate":-0.058482}],"exchange":"SEHK","name":"科济药业-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}